Cibus, Inc. Class A (CBUS)

Cibus, Inc. has experienced several stock events in the past six months. The company held its Q3 2025 and Q4 2025 financial results conference calls, with the stock declining after the Q3 announcement but showing positive movement after Q4. In January 2026, Cibus raised $22.3 million in gross proceeds from a public offering. As of March 18, 2026, the share price was $2.77, representing an increase of 16.88% over the previous year, and the stock has gained approximately 105% year-to-date. However, the stock price decreased by 11.74% on March 27, 2026, and has declined in 7 of the last 10 days.

The agricultural industry, in which Cibus, Inc. operates, is highly seasonal, causing fluctuations in sales and operating results. The sale of plant and seed products depends on growing and harvesting seasons, which vary across geographies due to weather. Climate change may further impact this seasonality by increasing the frequency or intensity of extreme weather events, affecting seed quality, volume, and cost, as well as demand and product mix. These factors can indirectly impact Cibus by potentially decreasing the quality and yields of seed containing its traits and reducing its licensees' available inventory, leading to lower royalty payments.

Cibus, Inc. is an agricultural technology company specializing in precision gene editing for agricultural applications, developing and licensing gene-edited plant traits to seed companies. Their technology platform, the Rapid Trait Development System (RTDS), is marketed under the "Trait Machine" brand name. Cibus develops plant traits that address productivity or yield challenges in farming. Major products and traits include SU Canola, a non-biotech canola tolerant to sulfonylurea herbicides, and the Falco seed brand in North America. The company has programs in rice, canola, soybean, and wheat, and is developing traits for potatoes, flax, and rice.

Cibus, Inc. is headquartered in San Diego, California, and serves customers and partners across North America and Europe. The company maintains research and development facilities dedicated to molecular biology, genomics, and field-based trait evaluation.

Cibus, Inc.'s brand reputation has been positively influenced by its technological advancements and strategic collaborations. The company's "Trait Machine" process was recognized by Fast Company Magazine, and Cibus was selected by the UK government as a technology partner. The EU's political agreement on new genomic techniques legislation is seen as opening significant market opportunities. The company's news sentiment score is 1.06, with increased news coverage in the week leading up to March 31, 2026.

Cibus, Inc. has 58 institutional owners and shareholders, holding a total of 12,012,354 shares. Major institutional owners include Fmr Llc, Vanguard Group Inc, and BlackRock, Inc. The ownership structure is a mix of institutional, retail, and individual investors, with Institutional Investors owning approximately 10.48% to 21.1%, Insiders owning 30.02% to 49.40%, and Public Companies and Individual Investors owning 51.9% to 56.72%. Rory Riggs owns the most shares of Cibus.